The ASX hit another record high on Tuesday, driven by consumer stocks. Meanwhile, Zip’s co-founder stepped down and biotech Invion soared.
The Victorian gold rush is far from dead and buried, with investors taking a shine to a new small-cap entrant.
On seemingly modest news, Invion shares have gone on a romp as investors grasp the potential of the undervalued cancer drug developer.
Auger drilling puts a spotlight on anomalies in the shadow of tens of millions of ounces of gold.
Altech’s updated valuation of 20c represents a 341% upside from its current share price of 4.6c due to progress made on two battery projects in Germany.
Lithium and nickel showed signs of life but most metals faltered in a November headlined by Donald Trump's US election win.
